Intravenous immunoglobulin (IVIG) as treatment for recurrent pregnancy loss (RPL)

Harefuah

Volumn 144, Issue 6, 2005, Pages 415-420

  Sapir, Tal ^a   Carp, Howard ^a,b   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cells natural killer (NK); IVIG; Recurrent abortion; Recurrent miscarriage

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

PREGNANCY; PREGNANCY DISORDER; RECURRENT DISEASE; REVIEW; SPONTANEOUS ABORTION; DRUG EFFECT; FEMALE; HUMAN; NIDATION; PHYSIOLOGY; RECURRENT ABORTION;

ABORTION, HABITUAL; EMBRYO IMPLANTATION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; PREGNANCY;

EID: 22444435142     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Daya S, Gunby J, Porter F & al, Critical analysis of intravenous immunoglobulin therapy for recurrent miscarriage. Hum Reprod Update, 1999; 5: 475-82.
2. Carp H, Toder V, Aviram A & al, Karyotype of the abortus in recurrent miscarriage. Fertil Steril, 2001; 75: 678-82.
3. Philipp T, Philipp K, Reiner A & al, Embryoscopic and cytogenetic analysis of 233 missed abortions: factors involved in the pathogenesis of developmental defects of early failed pregnancies. Hum Reprod, 2003 ;18: 1724-32.
4. Ogasawara M, Aoki K, Okada S & al, Embryonic karyotype of abortuses in relation to the number of previous miscarriages. Fertil Steril, 2000; 73: 300-4.
5. Carp H, Recurrent pregnancy loss: towards more accurate diagnosis and treatment. Isr Med Assoc J, 2001; 3: 528-32.
6. Stern JJ, Cerrillo M, Dorfmann AD & al, Frequency of abnormal karyotypes among abortuses from women with and without a history of recurrent spontaneous abortion. Fertil Steril, 1996; 65: 250-3.
7. Clark DA, Daya S, Coulam CB & al, Implication of abnormal human trophoblast karyotype for the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion. The Recurrent Miscarriage Immunotherapy Trialists Group. Am J Reprod Immunol, 1996; 35: 495-8.
8. Daya S & Gunby J, The effectiveness of allogeneic leukocyte immunization in unexplained primary recurrent spontaneous miscarriage. Am J Reprod Immunol, 1994; 32: 294-302.
9. Practice Committee of the American Society for Reproductive Medicine, Intravenous immunoglobulin (IVIG) and recurrent spontaneous pregnancy loss. Fertil Steril, 2004; 82 Suppl 1: 199-200.
10. Tartakover-Matalon S, Blank M, Matsuura E & al, Immunization of naïve mice with mouse laminin-1 affected pregnancy outcome in a mouse model. Am J Reprod Immunol (AJRI), 2003; 50: 159-165.
11. Omwandho CO, Gruessner SE, Roberts TK & al, Intravenous immunoglobulin (IVIG): modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders. Clin Chem Lab Med, 2004; 42: 359-70.
12. Shoenfeld Y & Krause I, IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J Clin Immunol, 2004; 24: 107-14.
13. Sherer Y, Levy Y & Shoenfeld Y, Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford), 2000; 39: 421-6.
14. Matalon ST, Blank M, Levy Y & al, The pathogenic role of antithyroglobulin antibody on pregnancy: evidence from an active immunization model in mice. Hum Reprod, 2003; 18: 1094-9.
15. Bakimer R, Gilburd B, Zurgil N & al, The effect of intravenous gammaglobulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol, 1993; 69: 97-102.
16. Dalakas MC, Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med, 1997; 126: 721-30.
17. Kazatchkine MD & Kaveri SV, Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med, 2001; 345: 747-55.
18. Krause I, Blank M & Shoenfeld Y, Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice. J Clin Immunol, 1998; 18: 52-60.
19. Altznauer F, von Gunten S, Spath P & al, Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol, 2003; 112: 1185-90.
20. Kekow J, Reinhold D, Pap A & al, Intravenous immunoglobulins and transforming growth factor beta. Lancet, 1998; 351: 184-5.
21. Sherer Y, Wu R, Krause I & al, Cytokine levels in various intravenous immunoglobulin (IVIG) preparations. Hum Antibodies, 2001; 10: 51-3.
22. Sherer Y, Levy Y & Shoenfeld Y, IVIG in autoimmunity and cancer - efficacy versus safety. Expert Opin Drug Saf, 2002; 1: 153-8.
23. Valensise H, Vaquero E, De Carolis C & al, Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG). Prenat Diagn, 1995; 15: 509-17.
24. Carp H, Asherson RA & Shoenfeld Y, Intravenous immunoglobulin in pregnancies complicated by the antiphospholipid syndrome: what is its role? J Clin Rheumatol, 2001; 7: 291-4.
25. Konova E, Andreeva H, Petrova P & al, Intravenous Immunoglobulin in the treatment of antiphospholipid-associated miscarriages - our experience. Clin Appl Immunol Investig, 2001; 1: 75-9.
26. Carp HJ, Ahiron R, Mashiach S & al, Intravenous immunoglobulin in women with five or more abortions. Am J Reprod Immunol, 1996; 35: 360-2.
27. Kwak JY, Kwak FM, Ainbinder SW & al, Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Am J Reprod Immunol, 1996; 35: 363-9.
28. Graphou O, Chioti A, Pantazi A & al, Effect of intravenous immunoglobulin treatment on the Th1/Th2 balance in women with recurrent spontaneous abortions. Am J Reprod Immunol, 2003; 49: 21-9.
29. Simon HU & Spath PJ, IVIG - mechanisms of action. Allergy, 2003; 58: 543-52.
30. Yamada H, Kishida T, Kobayashi N & al, Massive immunoglobulin treatment in women with four or more recurrent spontaneous primary abortions of unexplained aetiology. Hum Reprod, 1998; 13: 2620-3.
31. Ruiz JE, Kwak JY, Baum L & al, Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion. Am J Reprod Immunol, 1996; 35: 370-5.
32. Christiansen OB, Pedersen B, Rosgaard A & al, A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum Reprod, 2002; 17: 809-16.
33. Stricker RB, Steinleitner A, Bookoff CN & al, Successful treatment of immunologic abortion with low-dose intravenous immunoglobulin. Fertil Steril, 2000; 73: 536-40.
34. Carp HJ, Toder V, Gazit E & al, Further experience with intravenous immunoglobulin in women with recurrent miscarriage and a poor prognosis. Am J Reprod Immunol, 2001; 46: 268-73.
35. Coulam CB & Goodman C, Increased pregnancy rates after IVF/ET with intravenous immunoglobulin treatment in women with elevated circulating C56+ cells. Early Pregnancy, 2000; 4: 90-8.
36. Perino A, Vassiliadis A, Vucetich A & al, Short-term therapy for recurrent abortion using intravenous immunoglobulins: results of a double-blind placebo-controlled Italian study. Hum Reprod, 1997; 12: 2388-92.
37. Jablonowska B, Selbing A, Palfi M & al, Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study. Hum Reprod, 1999; 14: 838-41.
38. Stricker RB, Steinleitner A & Winger EE, Intravenous immunoglobulin (IVIG) therapy for immunologic abortion. Clin & Applied Immunol Rev, 2002; 2: 187-199.
39. Rauova L, Rovensky J & Shoenfeld Y, High dose intravenous immuoglobulins: a new step in the treatment of systemic lupus erythematosus. IMAJ, 2000; 2: 388-392.
40. Sipak-Szmigiel O, Ronin-Walknowska E & Miklaszwicz A, Application of intravenous immunoglobulin therapy (IVIG) in pregnant patients with recurrent spontaneous abortions. Ginekol Pol, 2003; 74: 350-5.